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Introduction  
The Liverpool Reviews and Implementation Group (LRiG) conducted six individual systematic reviews 
to examine the effectiveness and tolerability of systemic anti-cancer therapy used to treat older people 
with breast, colorectal, lung, renal cell, chronic myeloid leukaemia (CML) and non-Hodgkin’s 
lymphoma (NHL). The six individual reviews aimed to summarise relevant clinical evidence, 
disseminate accessible information to clinicians, and inform future clinical research priorities. The 
reviews primarily focussed on efficacy (e.g. overall survival, objective response), tolerability (e.g. 
relative dose intensity, withdrawals, and adverse events), but also collected data relating to quality of 
life (QoL), and the use of comprehensive geriatric assessment (CGA). A total of 490 studies were 
included across the six individual reviews, including evidence from 64 randomised controlled trials 
(RCTs). The largest review related to lung cancer (included studies, n=199) and the smallest review 
was for renal cell carcinoma (included studies, n=9). This paper, written by the review authors, presents 
a summary of the evidence relating to the reported use of CGA as described in the six reviews; the full 
methods and results of the individual six review publications can be accessed via the LRiG website 
(Liverpool Reviews and Implementation Group, 2016).  
Historically cancer treatments have had significant negative side effects and so their use has been 
frequently limited to younger and fitter patients. However, newer cancer treatments have fewer side 
effects and come with management algorithms means they are often preventable and are easier to 
manage when they do occur. As a result, chronological age alone is no longer considered an appropriate 
measure for determining an older person’s suitability for cancer treatment or for entry into a clinical 
trial. It is advocated by the International Society for Geriatric Oncology (SIOG) that CGA should be 
used in routine practice (International Society of Geriatric Oncology, 2016). CGA is a multidimensional 
process which involves the use of standardised measurement tools that can help to determine 
appropriate treatment choices for older people with cancer, to predict the side effects and potential 
complications of treatment, to improve patients’ mental health and physical wellbeing, and to estimate 
survival (Hurria and Cohen, 2016).  
Clinical studies often use CGA for a variety of purposes, such as to determine patient eligibility for 
trials or as an outcome measure to establish how well patients have responded to treatment in terms of 
how fit and well they are. When CGA is used appropriately it measures several domains, including 
functional status, comorbidity, cognitive function, psychological state, nutritional status, and levels of 
social support (Pallis et al., 2010, Hurria and Cohen, 2016). A large-scale study across 10 hospitals 
which used CGA to screen 1967 patients with cancer aged ≥70 years found that unknown age-related 
problems were uncovered, which allowed for early intervention  (25.7%) and changes in treatment 
decisions to benefit the patients (25.3%) (Kenis et al., 2012).  
  
Methods  
A comprehensive search strategy was developed, and four electronic databases (MEDLINE, EMBASE, 
The Cochrane Library, and Web Of Knowledge) were searched from January 2000 to May 2013 to 
systematically identify references for inclusion across the reviews. References were assessed for 
inclusion through two stages: two reviewers independently screened titles and abstracts for potentially 
relevant studies for each review (stage 1); full-text copies were obtained and independently assessed by 
two reviewers (stage 2). Disagreements were resolved by discussion with a third reviewer where 
necessary. Studies were excluded if they did not meet the inclusion criteria. 
The reviews included evidence from randomised controlled trials (RCTs), subgroup analyses of RCT 
data, pooled analyses, cohort studies, and retrospective data. The included population was ‘older’ or 
‘elderly’ people with lung cancer, NHL, colorectal cancer, breast cancer, CML and renal cell carcinoma. 
All forms of systemic anti-cancer therapy (including cytotoxic chemotherapy and biological agents) 
were considered and no restrictions were applied in terms of disease stage, tumour histology or the line 
of treatment across disease types.  
Data on a wide range of variables were extracted into piloted data extraction forms (quality assessment, 
study design, patient characteristics, efficacy outcomes, QoL, and CGA) by one reviewer, and checked 
for accuracy by a second reviewer. Disagreements were resolved through discussion with a third 
reviewer where necessary. The included RCTs were assessed for methodological quality using criteria 
based on the Centre for Reviews and Dissemination guidance (Centre for Reviews and Dissemination 
(CRD), 2008) and the non-randomised studies were not quality assessed.  
Findings  
There were 490 studies included across the six individual reviews: breast cancer (n=74), colorectal 
cancer (n=85), lung cancer (n=199), renal cell carcinoma (n=9), CML (n=15), and NHL (n=108). Fully 
detailed methodology, results, and findings are available in the individual review reports, including 
information relating to contributions from clinical advisors and co-authors (Liverpool Reviews and 
Implementation Group, 2016).  
There were very few studies across the six reviews which that explicitly reported the use of tools which 
the study authors had described as CGA. Information related to CGA use was reported in less than 10% 
(n=28) of studies overall, see Figure 1 for details. Individual study characteristics, details of the CGA 
tools used and how they were implemented are shown in Table 1. 
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Table 1 Study characteristics and CGA tools used 
 Study characteristics Tool(s) used, how tool(s) used 
Lung cancer 
LeCaer et al 2012 Phase II RCT 
France 
2006-2010 
CCI 
ADL 
IADL 
 
Used as eligibility criteria for patient 
selection 
Biesma et al 2011 Phase III RCT 
Netherlands 
2003-2006 
 
CCI 
ADL 
IADL 
CIRS-G 
TUG  
MMSE  
GDS-15 
PANAS  
GFI  
 
Baseline assessment and follow-up 
LeCaer et al 2011 Phase II RCT 
France 
2006-2008 
CCI 
ADL 
IADL 
 
Used as eligibility criteria for patient 
selection 
Gridelli et al 2003 Phase III RCT 
Italy 
1997-2000 
ADL 
IADL 
 
Baseline assessment and follow-up 
Gridelli et al 2012 
 
Phase I/II cohort study 
Italy 
2000-2005 
CCI 
ADL 
IADL 
 
Baseline assessment 
Camerini et al 
2010 
Phase II cohort study 
Italy 
2006-2009 
BADL 
IADL 
 
Used as eligibility criteria for patient 
selection 
LeCaer et al 2007 Phase II cohort study 
France 
2003-2004 
CCI 
 
Used as eligibility criteria for patient 
selection 
LeCaer et al 2007 Phase II cohort study 
France 
2003-2004 
CCI 
 
Used as eligibility criteria for patient 
selection 
Maestu et al 2007 Cohort study 
Spain 
2001-2003 
CCI 
IADL 
ADL 
 
Baseline assessment 
NHL 
Merli et al 2012 RCT 
Italy 
2003-2006 
IADL 
 
Baseline assessment 
Vitolo et al 2011 Cohort study 
Italy 
2004-2007 
Unspecified CGA 
 
Baseline assessment 
Bernardi et al 
2003 
(abstract only) 
Cohort study 
Italy 
2000-2002 
ADL 
IADL 
 
To categorise patients at enrolment in 
order to determine treatment regimen 
Tucci et al 2009 Cohort study 
Italy 
2003-2006 
ADL 
CIRS-G 
 
To categorise patients into fit/unfit 
Spina et al 2012 
 
Phase II cohort study 
Italy 
ADL 
IADL 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
FACT-L=Functional Assessment of Cancer Therapy for Lung Cancer; FACT-G=Functional Assessment of Cancer Therapy-
General; LCSS=Lung Cancer Symptoms Scale; CCI=Charlson Comorbidity Index; ADL=Activities of daily Living; 
IADL=Instrumental Activities of Daily Living; EORTC QLQ-C30=European Organisation for Research and Treatment of Cancer 
Quality of Life Cancer Questionnaire; EORTC QLQ-LC13=EORTC Quality of Life Cancer Questionnaire – Lung Cancer. TOI=Trial 
Outcome Index; TOI-L=Trial Outcome Index-Lung; KPS=Karnofsky performance status; CIRS-G=Cumulative Illness Rating Scale 
for Geriatrics; TUG=Timed Up and Go test; MMSE=Mini-Mental State Examination; GDS=Geriatric Depression Scale; 
PANAS=Positive and Negative Affect Schedule; GFI=Groningen Frailty Indicator; PSI=Pulmonary Symptom Improvement; 
QoL=quality of life; PS=performance status; NR=not reported 
2000-2006 
 
Geriatric depression 
MMSE  
CIRS-G  
 
As baseline measure and to categorise 
into fit/unfit 
Taoka et al 2010 Cohort study 
Japan 
2005-2009 
ADL 
 
Baseline assessment and follow-up 
Colorectal cancer 
Aparicio et al 
2011 
(abstract only) 
Phase III RCT 
2003-2010 
CCI 
MMSE 
IADL 
GDS 
 
Baseline assessment 
Sastre et al 2012 Phase III RCT subgroup 
2002-2004 
Independent Daily Activities Katz Scale 
 
Used as eligibility criteria for patient 
selection 
Carreca et al 
2011 
(abstract only) 
Cohort study 
2009 
Unspecified CGA 
 
Used as eligibility criteria for patient 
selection 
Feliu et al 2006 Cohort study 
Japan 
1999-2004 
CCI, ADL and IADL 
 
Baseline assessment 
Feliu et al 2005 Cohort study 
Spain 
2002-2002 
ADL 
 
Baseline assessment and follow-up   
Mattioli et al 2005 Phase II cohort study 
Italy 
2001-2004 
ADL, IADL 
 
Baseline assessment and follow-up 
Rosati et al 2005 Phase II cohort study 
Italy 
2002-2004 
ADL 
IADL 
 
Baseline assessment 
Comella et al 
2005 
Phase II cohort study 
Italy 
2001-2004 
ADL, MMS, CCI 
 
Baseline assessment and follow-up 
Daniele et al 2003 Cohort study 
Italy 
1998-2000 
ADL, IADL 
 
Baseline assessment 
Breast cancer  
Romieu et al 2007 Phase II RCT 
France, Germany, Spain, 
UK, Switzerland 
2002-2004 
VES-13  
 
Baseline assessment and follow-up 
Nuzzo et al 2008 Phase III RCT 
Italy 
2003-2006 
IADL 
ADL 
 
Baseline assessment and follow-up 
Hurria et al 2006 Cohort study 
USA 
2001-2003 
ADL, IADL, GDS, CCI, BMI 
 
Baseline assessment and follow-up 
Renal cell carcinoma 
Brunello et al 
2013 
Retrospective review  
Italy 
2006-2010 
CIRS-G  
 
Used as baseline measure to stratify 
patients into fit/vulnerable/frail 
categories 
  
As shown in Table 1, there were 11 different tools used for the purpose of CGA across the included 
studies, used either in combination or stand alone: Charlson Comorbidity Index (CCI), Activities of 
Daily Living (ADL), Instrumental Activities of Daily Living (IADL), Basic Activities of Daily Living 
(BADL), Cumulative Illness Rating Scale for Geriatrics (CIRS-G), Timed Up and Go Test (TUG), 
Mini-Mental State Examination (MMSE), Geriatric Depression Scale (GDS), Positive and Negative 
Affect Schedule (PANAS), Groningen Frailty Indicator (GFI), Vulnerable Elders Survey (VES-13), 
Independent Daily Activities Katz Scale.  
Comprehensive geriatric assessment was implemented in a number of different ways across the 
included studies, as shown in Table 1. Eight studies used CGA as a baseline assessment measure in a 
similar way to disease stage or performance status (Daniele et al., 2003, Rosati et al., 2005, Feliu et al., 
2006, Maestu et al., 2007, Aparicio et al., 2011, Vitolo et al., 2011, Gridelli et al., 2012, Merli et al., 
2012). Nine studies used CGA to assess patients at baseline and at as follow-up different time points 
(Gridelli et al., 2003, Comella et al., 2005, Feliu et al., 2005, Mattioli et al., 2005, Hurria et al., 2006, 
Romieu et al., 2007, Nuzzo et al., 2008, Taoka et al., 2010, Biesma et al., 2011); seven studies used 
CGA tools as an assessment for eligibility in the study (LeCaer et al., 2007a, LeCaer et al., 2007b, 
Camerini et al., 2010, Carreca et al., 2011, LeCaer et al., 2011, LeCaer et al., 2012, Sastre et al., 2012); 
and four studies used CGA tools to categorise patients into subgroups for the purpose of data analysis 
(Bernardi et al., 2003, Tucci et al., 2009, Spina et al., 2012, Brunello et al., 2013).  
Discussion 
Overall, the reviews highlight a paucity of published data relating to the use of CGA tools in clinical 
study settings, which may be reflective of the lack of use in routine clinical practice. According to the 
clinicians advising the review team, the practicalities of conducting CGA assessment (usually by a 
clinical nurse specialist) are often considered time consuming and resource intensive and, as such, CGA 
is often not conducted in practice and is not routinely incorporated into the protocol for cancer study 
trials. Perhaps this is also in part due to the fact that gerontology and oncology have only (relatively) 
recently been linked in clinical practice (Birmingham, 2006).  SIOG advocate the use of CGA in routine 
practice (International Society of Geriatric Oncology, 2016) as it enables clinicians to determine 
appropriate treatment choices for older people with cancer, which in turn leads to better outcomes in 
terms of benefit to the patients. It is therefore imperative that the routine use of CGA be incorporated 
into future research and is on the agenda for clinical nurse specialists. 
The six reviews identified several CGA tools used in clinical studies, and with the exception of PANAS 
and BADL, the majority have been identified as commonly used CGA tools (Pallis et al., 2010, 
International Society of Geriatric Oncology, 2016). There are other commonly used CGA tools that are 
available to clinicians, which were not used in the included studies included in this review. For example: 
G8 Questionnaire, Mini Nutritional Assessment (MNA), Barthel Index, Senior Adult Oncology 
  
Program, Adult Comorbidity Evaluation, MAX2 Index, 6-minute walk test, Short Portable Mental 
Status, and the Blessed Dementia Ratings Scale (Pallis et al., 2010, International Society of Geriatric 
Oncology, 2016).  
All information relating to a patient’s potential wellbeing and response to treatment is important when 
treatment decisions are being made as each individual’s comorbidities and fitness need to be considered. 
How this information was collected and collated by investigators was often not adequately described in 
the studies included in the six reviews and, when presented, the reporting of CGA was poor and 
inconsistent. For example, it is not sufficient for study authors to specify which tools have been used, 
it is also useful for study authors to describe how, when and why CGA was undertaken.  
Implications for future research 
The general consensus of the clinical advisors who worked across the reviews is that the development 
and validation of specific CGA tools is required for use in UK clinical practice if a clearer picture of 
the eligibility of older people for treatment is to be communicated to the wider clinical community. This 
approach will also inform clinicians as to the specific experiences of older people receiving treatment 
for cancer. Perhaps the challenge is for nurses and clinical nurse specialists, who are at the front line of 
services for older people with cancer, to implement changes in routine practice. However, if routine use 
of CGA is time consuming and resource intensive, future research might need to focus on a streamlined 
and unified approach which balances resource use and patient benefit.  
The reviews highlight that (chronological) age in itself should not be the only factor considered when 
choosing appropriate treatments for patients, therefore it is essential that reliable measures of fitness 
and comorbidity (characteristics of biological age) are developed and used consistently in both clinical 
trial settings and routine practice. The increased use of CGA in clinical practice could mean that a higher 
number of older patients are offered treatment, and an increase in the use of CGA in clinical studies 
could improve the numbers of older patients who are eligible for trials.   
Conclusions  
Findings from across the five reviews that included CGA-related information show that CGA is not 
routinely carried out in clinical trials and that the CGA data that are collected are limited. The 
incorporation of standardised CGA tools into the design of future clinical trials that include older 
patients will be key to the success of future research into the treatment of older people with cancer. 
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